VALN vs. CABA, ALEC, PROK, ALLO, HUMA, TSHA, FATE, PRME, EXAI, and CCCC
Should you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Cabaletta Bio (CABA), Alector (ALEC), ProKidney (PROK), Allogene Therapeutics (ALLO), Humacyte (HUMA), Taysha Gene Therapies (TSHA), Fate Therapeutics (FATE), Prime Medicine (PRME), Exscientia (EXAI), and C4 Therapeutics (CCCC). These companies are all part of the "biological products, except diagnostic" industry.
Cabaletta Bio (NASDAQ:CABA) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.
Cabaletta Bio has a net margin of 0.00% compared to Cabaletta Bio's net margin of -15.88%. Cabaletta Bio's return on equity of -14.56% beat Valneva's return on equity.
11.4% of Valneva shares are owned by institutional investors. 9.9% of Cabaletta Bio shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cabaletta Bio has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Valneva has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.
Cabaletta Bio has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Valneva had 7 more articles in the media than Cabaletta Bio. MarketBeat recorded 14 mentions for Valneva and 7 mentions for Cabaletta Bio. Valneva's average media sentiment score of 1.01 beat Cabaletta Bio's score of 0.53 indicating that Cabaletta Bio is being referred to more favorably in the media.
Cabaletta Bio received 52 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 69.44% of users gave Cabaletta Bio an outperform vote while only 52.27% of users gave Valneva an outperform vote.
Cabaletta Bio presently has a consensus price target of $34.33, indicating a potential upside of 204.91%. Valneva has a consensus price target of $21.67, indicating a potential upside of 192.00%. Given Valneva's higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Valneva.
Summary
Cabaletta Bio beats Valneva on 9 of the 16 factors compared between the two stocks.
Get Valneva News Delivered to You Automatically
Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
